



Xience Prime Everolimus-Eluting Coronary Stent System

COMPANY	Abbott Vascular
PHONE	(800) 227-9902
WEB	www.abbottvascular.com
KEY FEATURES • Enhanced stent design and delivery system • Excellent radial and longitudinal strength • Broad size matrix includes long lengths (38 mm) • Supported by data from the SPIRIT family of trials	

The next-generation Xience Prime everolimus-eluting coronary stent system (Abbott Vascular, Santa Clara, CA)

recently received US Food and Drug Administration approval for the treatment of coronary artery disease. Xience Prime, which uses the same drug and biocompatible polymer as the Xience V everolimus-eluting coronary stent system, features an enhanced stent design and a delivery system that is designed for greater flexibility, radial strength, longitudinal strength, and more accurate stent placement.

"Drug-eluting stent technology continues to advance, leading to improved outcomes for patients with coronary artery disease," said Marco Costa, MD, PhD, Principal Investigator of the global SPIRIT PRIME trial. "With Xience Prime, for the first time in the United States, physicians have a 38-mm everolimus-eluting stent for the treatment of long lesions. The enhanced deliverability and wide range of sizes, including a small-vessel 2.25-mm-diameter stent, will improve our ability to access challenging, complex lesions and thereby improve care for our patients."



Promus Element Plus Everolimus-Eluting PtCr Coronary Stent System

COMPANY	Boston Scientific Corporation
PHONE	(888) 272-1001
WEB	www.bostonscientific.com
KEY FEATURES • Effective drug and polymer combination • Innovative platinum chromium (PtCr) alloy offers increased strength • Unmatched radial strength and minimal recoil • Enhanced conformability, deliverability, and visibility • Greater pushability and trackability than cobalt alloy	

Boston Scientific Corporation (Natick, MA) announced the launch of the Promus Element Plus everolimus-eluting platinum chromium coronary stent system. This system establishes a new standard of drug-eluting stent performance with the combination of its highly visible platinum chromium alloy, innovative stent design, and enhanced stent delivery system, plus an everolimus drug and fluorinated copolymer combination.

Prior to use in the United States, please see the complete "Directions for Use" at www.bostonscientific.com for more information on indications, contraindications, warnings, Precautions, Adverse Events, and Operator's Instructions. Indications, contraindications, warnings, precautions and instructions for use can be found in the product labeling supplied with each device. IC-64202-AA FEB2012 ■

